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ABSTRACT
 
Cellular carriers meet several desirable criteria in 
clinical applications, among the most important being 
the carrier's biocompatibility and its degradation 
products, the various carriers used to target drugs to 
different body tissues. Among these, the most studied 
erythrocytes have been shown to have greater potential 
in the delivery of drugs here are currently 30 major 
products on the market to deliver drug. Carrier 
erythrocytes have been evaluated for the safety and 
efficacy of treatments in thousands of human drug 
administration. Because of their remarkable degree of 
biocompatibility, biodegradability and a number of 
other potential benefits, carrier erythrocytes, resealed 
erythrocytes charged by a drug or other therapeutic 
agents have been extensively exploited in recent years 
to provide a wide range of drugs and other bioactive 
agents temporally and spatially controlled. 
Biopharmaceuticals, therapeutically significant 
peptides and proteins, biological, antigens, and nucleic 
acid-based vaccines are among the recently targeted 
drugs for delivery using erythrocyte carriers. Carrier 
erythrocytes are prepared by collecting blood samples 
from the organism of intreast and separating plasma 
erythrocytes. The cells are separated by different 
methods and the product is retained in the erythrocytes, 
they are eventually resealed and the resulting carriers 
are then labeled "resealed erythrocytes". Recent 
research focuses on isolation, methods of drug 
processing, testing methods and drug delivery resealed 
erythrocyte applications. 
 
Keywords: Characterization methods, drug targeting, 
isolation and applications, resealed erythrocytes 
 
INTRODUCTION 
Blood contains various types of cells such 
as erythrocytes (RBC), leucocytes (WBC) 
and platelets, including erythrocytes, 
which are the most interesting carrier and 
possess great potential for drug delivery 
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due to their ability to circulate throughout 
the body, zero-order kinetics, 
reproducibility and easy preparation. [1]. 
The overall process is based under osmotic 
conditions on the response of these cells. 
The drug-charged erythrocytes function as 
slow circulating depots after reinjection 
and direct the drugs to tissue or organ 
disease. The objective of the current 
pharmaceutical scenario is to construct 
drug delivery systems that optimize drug 
targeting along with high therapeutic 
benefits for safe and effective management 
of disease. Targeting an active bio 
molecule from the successful delivery of 
drugs where the pharmacological agent 
specifically targets its target site. Drug 
targeting can be either by chemical 
modification or by a suitable carrier. 
 
Erythrocytes 
Red blood cells (also known as 
erythrocytes) are the most common type of 
blood cells and the main means of 
delivering oxygen (O2) through the 
circulatory system to the body tissues 
through the blood flow. In the bone 
marrow, the cells mature and circulate in 
the body for about 100–120 days until 
macrophages reuse their components. It 
takes about 20 seconds for each 
circulation. About a quarter of the human 
body's cells are red blood cells [2]. 
 
Anatomy, physiology and composition 
of RBC’s 
RBC's have shapes such as 7.8 μm 
diameter biconcave disks and about 2.2 
μm thickness. There is a simple structure 
for mature RBCs. By nature, it's also 
elastic. Their plasma membrane is both 
strong and flexible, allowing them to 
squeeze through narrow capillaries without 
rupturing. RBCs lack a nucleus and other 
organelles and are unable to replicate or 
perform extensive metabolic activity. For 
their oxygen transport function, RBCs are 
highly specialized because their mature 
RBCs do not have a nucleus, and all their 
internal space is available for oxygen 
transport. Even the design of the RBC 
equipment it operates [13]. For the 
movement of gas molecules into and out of 
the RBC, a biconcave disk has a much 
larger surface area than it would; say a 
sphere or cube. The red blood cell 
membrane, a complex, semi-permeable 
cell element associated with energy 
metabolism in maintaining the cell's 
permeability characteristics of different 
cations (Na+, K++) and anions (Cl-HCO-). 
Each RBC contains about 280 million 
hemoglobin molecules. A hemoglobin 
molecules consists of a protein called 
globin, composed of four polypeptide 
chains; each of the four chains is bound to 
a non-protein-like pigment called a heme. 
Combine reversibly with one oxygen 
molecule at the center of the heme chain 
so that each hemoglobin molecule binds 
four oxygen molecules. RBCs include 
water (63%), lipids (0.5%), glucose 
(0.8%), minerals (0.7%), non-hemoglobin 
(0.9%), meth hemoglobin (0.5%) and 
hemoglobin (33.67%). 
 
Resealed Erythrocytes 
The drug-loaded carrier erythrocytes are 
prepared simply by collecting blood 
samples from the interesting organism, 
separating erythrocytes from plasma, 
trapping drugs in the erythrocytes, and 
resealing the resulting cell carriers. Such 
carriers are therefore referred to as 
resealed erythrocytes [3]. The overall 
process is based under osmotic conditions 
on the response of these cells. The drug-
charged erythrocytes act as slow 
circulating depots after reinjection and 
target the drugs to a reticuloendothelial 
system (RES). 
 
Source of Erythrocytes 
Various types of mammalian erythrocytes, 
including mice, cattle, pigs, dogs, sheep, 
goats, monkeys, chicken, rats, and rabbits, 
have been used for drug delivery. 
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Isolation of Erythrocytes 
Erythrocytes can be prepared as carriers of 
human and animal blood, such as rodents, 
mice, rabbits, cats, etc. Blood is obtained 
from the corresponding human, mouse, 
rodent, or animal species using an 
effective anti-coagulant. EDTA is typically 
used as an anticoagulant that better 
protects the properties of blood cells. In a 
refrigerated centrifuge, freshly collected 
blood is centrifuged to isolate packed 
erythrocytes [11]. Subsequently, several 
washes are performed. This is a process 
that usually involves repeated 
centrifugation with a solution for removing 
other components of the blood. By using a 
capillary hollow fibre plasma separator, 
the erythrocytes can be washed more 
efficiently. The hematocrits employed can 
vary from 5% to 95% [6]. Although the 
most common thing is to work with a 70% 
hematocrit. In 1953, using adenosine 
triphosphate (ATP), Gardos tried to load 
erythrocyte ghost. In 1959, dextran 
(molecular weight 10–250 kDa) was 
reported by Marsden and Ostting. In 1973, 
Ihler et al. and Zimmermann separately 
reported the loading of drugs into 
erythrocytes. In 1979, to characterize drug-
loaded erythrocytes, the term carrier 
erythrocytes was coined. 
 
Requirement for Encapsulation 
Biologically active substance variety 
(5000-60,000dalton) may be trapped in 
erythrocytes. 
 Non-polar molecule may be trapped in 
salt erythrocytes. Example: 
tetracycline HCl salt in bovine RBC 
can be significantly trapped [12]. 
 Generally speaking, the molecule 
should also be trapped with Polar & 
Non Polar molecule. 
 Once the charged molecule is 
encapsulated, it will hold longer than 
the unloaded molecule. When the 
molecule is smaller than sucrose and 
larger than B-galactosidase, the size of 
the trapped molecule is a significant 
factor. 
 Various condition and centrifugal force 
used for isolation of erythrocytes. 
 
METHODS OF DRUG LOADING IN 
ERYTHROCYTES 
Hypo-osmosislysis Method 
In this process, osmotic lysis and resealing 
is exchanged for the intracellular and 
extracellular solution of erythrocytes. This 
process will encapsulate the drug present 
in the RBCs. 
 
Hypotonic Dilution 
A amount of packed erythrocytes is 
combined in this process with 2–20 
volumes of a drug's aqueous solution. 
Then a hypertonic buffer is added to 
restore the tonicity of the solution. The 
resulting mixture is then centrifuged, 
the supernatant is discarded, and the 
isotonic buffer solution washes the 
pellet.
 
 
Figure 1: Hypotonic dilution. 
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Hypotonic Dialysis Method 
Klibansky first reported this method in 
1959 and Deloach, Ihler and Dale used 
this method in 1977 to load enzymes 
and lipids. In this process, an isotonic, 
buffered erythrocyte suspension with a 
hematocrit value of 70–80 is prepared 
and placed in a conventional 10–20 
volume dialysis tube of a hypotonic 
buffer [4]. The medium is steadily 
disturbed for 2 hours. The tonicity of 
the dialysis tube is restored by adding 
directly to the surrounding medium a 
calculated amount of a hypertonic buffer 
or by replacing the surrounding medium 
with an isotonic buffer. The drug to be 
loaded can be added either by dissolving 
the drug inside a dialysis bag at the 
beginning of the experiment in an 
isotonic cell suspending buffer or by 
adding the drug to a dialysis bag after 
the stirring is complete. 
 
 
Figure 2: Hypotonic dialysis. 
 
Hypotonic Press Welling Method 
Rechsteiner invented this approach in 1975 
and was updated for drug charging by 
Jenner et al. By positioning them in a 
slightly hypotonic solution, this approach 
is based on the principle of first swelling 
the erythrocytes before lysis. The swollen 
cells are recovered at low speed through 
centrifugation. Instead relatively small 
amounts are added to the point of lysis of 
aqueous drug solution. The slow swelling 
of cells leads to good preservation of 
cytoplasmic components and therefore 
good in vivo survival. Simpler and quicker 
than other approaches, this approach 
causes minimal damage to cells. This 
method includes propranolol, asparginase, 
cyclopohphamide, methotrexate, insulin, 
metronidazole, levothyroxine, enalaprilate 
& isoniazid. 
 
 
Figure 3: Hypotonic press well method.
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Isotonic Osmotic Lysis Method 
This method was documented by Schrier 
et al., in 1975. This technique, also known 
as the osmotic pulse process, involves 
isotonic hemolysis by physical or chemical 
means. It may or may not be solutions that 
are isotonic. Because of the gradient of 
concentration, if erythrocytes are 
incubated in the solutions of a substance 
with high membrane permeability, the 
solution will diffuse into the 
cells.Following this process is an influx of 
water to maintain osmotic balance. Of 
isotonic hemolysis, chemicals such as urea 
solution, polyethylene glycol, and 
ammonium chloride were used. This 
method is also not immune to changes in 
the composition of the membrane 
structure, however. Franco et al., 
developed a method in 1987 involving the 
suspension of erythrocytes in a dimethyl 
sulfoxide (DMSO) isotonic solution. The 
suspension was combined with a drug 
solution isotonically buffered. They were 
sealed at 370°C after the cells had been 
separated (Fig. 4). 
 
 
Figure 4: Isotonic osmotic lysis. 
 
Electro-insertion or Electro 
Encapsulation Method 
In 1973, Zimmermann attempted to 
encapsulate bioactive molecules using an 
electrical pulse technique. Also known as 
electroporation, the method is based on the 
observation of irreversible changes in an 
erythrocyte membrane caused by electrical 
shock. Also called this method as an 
electroporation. Erythrocyte membrane is 
opened by a dielectric breakdown in this 
method; erythrocyte pore can subsequently 
be resealed in an isotonic medium at 
370°C by incubation. Primaquine and 
related 8-amino quinolone, vinblastin 
chloropromazine and related 
phenothiazine, propanolol, tetracaine, and 
vitamin A are the different chemicals 
encapsulated in the erythrocytes. 
 
Entrapment by Endocytosis 
Schrier et al reported this method in 1975. 
This method involves adding one volume of 
washed packed erythrocytes to nine volumes 
of 2.5MM ATP, 2.5MM mgcl2 and 1MM 
CaCl2 buffer, followed by incubation at room 
temperature for 2 minutes. By using NaCl 
154MM, the pores created by this method are 
resealed and incubated for 2 minutes at 
370°C. This method involves primaquine and 
related8-aminoquinoline, vinblastin, 
chlorpromazine, and related phenothiazines, 
hydrocortisone, tetracaine, and vitamin A.
  
26 Page 21-30 © MAT Journals. All Rights Reserved 
 
Journal of Pharma and Drug Regulatory Affairs  
e-ISSN: 2582-3043 
Volume 2, Issue 1 
 
 
Figure 5: Entrapment by endocytosis. 
 
Chemical Perturbation of the 
Membrane 
This approach is based on the increase in 
erythrocyte membrane permeability when 
exposed to certain chemicals by the cells. 
In 1973, Deuticke et al. showed that when 
exposed to polyene antibiotics such as 
amphotericin B, the permeability of 
erythrocyte membrane increases. In 1980, 
this approach was successfully used in 
human and mouse erythrocytes by Kitao 
and Hattori to capture the antineoplastic 
drug daunomycin [5]. These methods, 
however, induce irreversible destructive 
changes in the membrane of the cells and 
are therefore not very popular. 
 
Lipid Fusion Method 
The lipid vesicles containing a drug may 
be fused directly to human erythrocytes, 
resulting in an exchange with a drug 
trapped in lipid 161. The methods are 
useful for clogging monophasphate 
inositol to improve cell oxygen carrying 
capacity and this method's clogging 
efficiency is very low (~1%). 
 
Loading by Electric Cell Fusion 
This method involves the initial loading into 
erythrocyte ghosts of drug molecules 
accompanied by adherence of these cells to 
target cells. Applying an electrical pulse, 
which causes the release of a trapped 
molecule, accentuates the fusion. An example 
of this approach is the loading into an 
erythrocyte ghost of a cell-specific 
monoclonal antibody. An antibody against a 
specific targetcell surface protein may be 
chemically linked to drug-charged cells that 
would guide these cells to targeted cells.
 
 
Figure 6: Loading by electric cell fusion. 
 
Use of Red Cell Loader 
Novel method for trapping non-diffusible 
drugs in erythrocytes has been established. 
A piece of equipment called a "red cell 
loader" was created. With as little as 50 ml 
of a blood sample, under blood banking 
conditions, various biologically active 
compounds were caught in erythrocytes 
Erythrocyte Drug 
Drug loaded Erythrocyte 
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within 2 h at room temperature. The 
process is based on two simultaneous 
hypotonic dilutions of washed erythrocytes 
followed by a hem filter concentration and 
isotonic cell resealing. For 35–50 per cent 
cell regeneration, there was 30% drug 
charging. The erythrocytes that were 
treated had natural in vivo survival. 
Through enhancing their identification by 
tissue macrophages, the same cells could 
be used for targeting. 
 
STORAGE 
Store encapsulated preparation without 
loss of integrity when suspended in hank's 
balanced salt solution [HBSS] at 4°C for 
two weeks. Use of group 'O' [universal 
donor] cells and by using the preswell or 
dialysis technique, batches of blood for 
transfusion. Standard blood bag may be 
used for both encapsulation and storage 
[14]. 
 
APPLICATIONS OF RESEALED 
ERYTHROCYTES 
In-Vitro Application 
To order to facilitate the absorption of 
enzymes, phagocytosis cells were used to 
in vitro. Using cytochemical technique, 
enzymes within carrier RBC could be 
visualized. Deficiencies such as the 
deficiency of glucose-6-phosphate 
dehydrogenase (G6PD) may be a useful 
tool to discern the mechanism that 
ultimately causes these effects. RBC's 
most commonly used in vitro is 
microinjection. A fusion process injected a 
protein or nucleic acid into eukaryotic 
cells [6]. Likewise, they propagate rapidly 
throughout the cytoplasm when antibody 
molecules are added using erythrocytic 
carrier method. Auto-injected RBC 
antibody into living cells was used to 
validate the toxin fragment's site of action. 
Antibodies introduced using RBC 
mediated microinjection are recorded to 
prevent entry into the nucleus, limiting the 
studies to cytoplasmic level. In-Vivo 
Application: 
Targeting of Bioactive Agents to RE 
System 
The phagocyte Kuffer cells in the liver and 
spleen quickly clear up damaged 
erythrocytes from circulation. Thus, 
resalted erythrocytes can be used to target 
the liver and spleen by modifying their 
membranes. The different approaches to 
modifying erythrocyte surface 
characteristics include surface 
modification with antibodies, 
gluteraldehyde, carbohydrates such as 
sialic acid and sulphydryl. 
 
Targeting to Sites as Other Than RES 
Organ 
Resealed erythrocytes have the ability to 
supply the macrophage-rich with a drug or 
enzyme. Resealed erythrocytes have 
recently been used to test organs targeting 
other than RES. Some of the approaches to 
representation are discussed briefly. 
 
Targeting the Liver 
Deficiency / replacement of enzyme 
therapy. Through administering these 
enzymes, most metabolic conditions 
associated with defective or absent 
enzymes can be controlled. Exogenous 
enzyme therapy problems, however, 
include shorter enzyme distribution, 
allergic reactions, and are toxic [7]. The 
enzymes used include glycosidase, 
glucuronidase, and galactosidase4, which 
can be successfully solved by 
administering the enzymes as resealed. 
Glucocerebrosi-dase-loaded erythrocytes 
can treat the disease caused by an 
accumulation of glucocerebroside in the 
liver and spleen [3]. 
 
Slow Drug Release 
Erythrocytes have been used as circulating 
depots to provide antineoplastics, 
antiparasitic, veterinary antiamoebics, 
vitamins, hormones, antibiotics and 
cardiac drugs on an ongoing basis 
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Drug Targeting 
Ideally, in order to achieve optimum 
therapeutic index with minimal adverse 
effects, drug delivery should be site-
specific and target driven. Resealed 
erythrocytes can also function as drug 
carriers and target devices. Modified 
surface erythrocytes are used to target 
mononuclear phagocytic system / RES 
organs because macrophages recognize the 
change in the membrane. 
 
Targeting Liver-Deficiency/Therapy 
Through administering these enzymes, 
most metabolic disorders associated with 
defective or absent enzymes can be treated 
[15]. However, problems with exogenous 
enzyme therapy include shorter half-life 
enzyme circulation, allergic reactions, and 
toxic manifestations. By administering 
resealed erythrocytes to the enzymes, these 
problems can be successfully overcome. P-
glucosidase, P-glucoronidase, and P-
galactosidase are the enzymes that are 
used. Glucocerebrosidase-load d 
erythrocytes may treat the disease caused 
by an accumulation of glucocerebroside in 
the liver and spleen. 
 
Removal Toxic Agents 
Inhibition of cyanide poisoning with 
murine carrier erythrocyte containing 
bovine rhodanase and sodium thiosulphate 
was reported by Cannon et al. It has also 
been reported that organophosphorus 
poisoning has been antagonized by 
released erythrocyte with recombinate 
phosphodiestrase. 
 
ROUTE OF ADMINISTRATION 
The intra-peritoneal injection was stated to 
be similar to the cells administered by i.v. 
Injection. They reported that 25% of the 
resealed cell remained in circulation for 14 
days as a method for extra-vascular 
targeting of RBCs to peritoneal 
macrophages. Subcutaneous way to release 
trapped agents slowly [8]. They reported 
that encapsulated molecules were released 
at the injection site by the loaded cell. 
EVALUATION OF RESEALED 
ERYTHROCYTES 
Shape and Surface Morphology 
After administration, the morphology of 
erythrocytes determines their life span. In 
comparison to untreated erythrocytes, the 
morphological characterization of 
erythrocytes is conducted using either 
transmission (TEM) or scanning electron 
microscopy (SEM). Certain techniques, 
such as phase contrast microscopy, can 
also be used [9]. 
 
Drug Content 
Cell drug content determines the 
effectiveness of the method used in 
trapping. The process involves 
deproteinizing sealed, packed cells (0.5 
mL) with 2.0 mL acetonitrile and 10 min 
at 2500 rpm centrifugation. 
Spectrophotometrically, the clear 
supernatant is analyzed for the drug 
content. 
 
Cell Counting and Cell Recovery 
This includes counting the number of red 
blood cells per unit volume of whole 
blood, which is typically calculated by 
counting the number of intact cells per 
cubic mm of packed erythrocytes before 
and after the medication is loaded using an 
automated system. 
 
Turbulence Fragility 
It is determined by passing cell suspension 
through smaller inner diameter needles 
(e.g. 30 gauges) or shaking the cell 
suspension vigorously[10]. In both cases, 
after the process is determined, 
haemoglobin and medication released. 
Resealed cells ' chaotic fragility is found to 
be higher. 
 
Erythrocyte Sedimentation Rate  
It is an approximation of RBC's 
suspension stability in plasma and is 
related to the number and size of red cells 
and related plasma protein concentration, 
especially fibrinogen and α, β globulins. 
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This experiment is carried out by 
evaluating the sedimentation level in a 
typical pipe of blood cells. Normal ESR 
blood is between 0 and 15 mm / h. 
Indications of active but obscure disease 
processes are higher rates. 
 
Determination of Entrapped Magnetite 
For determining the concentration of 
specific metal in the sample, atomic 
absorption spectroscopic method is 
reported. Using atomic absorption 
spectroscopy, the HCl is added to a fixed 
amount of magnetite bearing erythrocytes 
and content is heated at 600C for 2 hours, 
then 20% w / v trichloro acetic acid is 
added and supernatant is obtained after 
centrifugation. 
 
Haemoglobin Release 
During the encapsulation process, the 
haemoglobin content of the erythrocytes 
may be decreased by changes in the 
permeability of the red blood cell 
membrane. In addition, the relationship 
between the haemoglobin concentration 
and the drug release rate of the 
erythrocyte-encapsulated material. The 
leakage of haemoglobin is checked with a 
red cell suspension through absorption 
 
In-vitro Drug Release and Hb Content 
The cell suspensions are stored at 40°C in 
ambered glass container (5% hematocrit in 
PBS). Periodically clear supernatants are 
drawn using a 0.45 filtered hypodermic 
syringe, deprotected using methanol, and 
far-reaching drug content has been 
estimated. The supernatant of each sample 
can be measured using formula percent Hb 
release= A540 of 100% Hb history test-
A540 after centrifugation collected and 
assayed [16-19]. 
 
CONCLUSION 
The use of resealed erythrocytes has a very 
good result for a safe and secure 
distribution for passive and active 
targeting of different drugs. The concept 
requires more refinement in order to 
become a standard drug delivery method 
and we can also use the same principle to 
expand the delivery of biopharmaceuticals 
and much remains to be explored as to the 
ability of resealed erythrocytes. It's very 
easy to prepare resealed erythrocytes. Now 
a day has been identified with several 
strategies that we can quickly trap the drug 
into erythrocytes. It has both in-vitro and 
in-vivo form of application. 
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